Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia

Infection

Volumn 41, Issue 2, 2013, Pages 517-523

  Griffin, A T ^a   Peyrani, P ^a   Wiemken, T L ^a   Ramirez, J A ^a   Arnold, F W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Community acquired pneumonia; Intensive care; MRSA

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; EMPIRICAL RESEARCH; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84879502052     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0363-1     Document Type: Article

References (20)

1. Rubinstein E, Kollef M, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46:S378-85.
2. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 1997;40:100-7.
3. Brulé N, Jaffré S, Chollet S, Germaud P, Chailleux E. Necrotizing pneumonia due to Staphylococcus aureus producing Panton-Valentine toxin. Rev Mal Respir. 2008;25:875-9.
4. Lobo L, Reed K, Wunderink R. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest. 2010;138:130-6.
5. Salgado CD, Farr BM, Calfee DM. Community-acquired methicillin resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36:131-9.
6. Faria NA, Oliveira DC, Westh H. Epidemiology of emerging methicillin-resistant Staphylococcus aureus (MRSA) in Denmark: a nationwide study in a country with low prevalence of MRSA infection. J Clin Microbiol. 2005;43:1836-42.
7. Thomas R, Ferguson J, Coombs G, Gibson PG. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit. Respirology. 2011;16:926-31.
8. Li HT, Zhang TT, Huang J, Zhou YQ, Zhu JX, Wu BQ. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration. 2011;81:448-60.
9. Woodhead M, Blasi F, Ewig S, Garau J, et al. Guidelines for the management of adult lower respiratory tract infections-summary. Clin Microbiol Infect. 2011;17:1-24.
10. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:e18-55.
11. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
12. Lim WS, van der Eerden MM, Laing R, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82.
13. Imai K, van Dyk D. Causal inference with general treatment regimes: generalizing the propensity score. J Am Stat Assoc. 2004;99:854-66.
14. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-6.
15. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133:610-7.
16. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest. 2000;118:1344-54.
17. Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther. 2010;32:293-9.
18. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America; American thoracic society. Infectious diseases society of America/American thoracic society guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27-72.
19. Bodí M, Rodríguez A, Solé-Violán J, et al. Community-acquired pneumonia intensive care units (CAPUCI) study investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to infectious diseases society of America guidelines on survival. Clin Infect Dis. 2005;14:1709-16.
20. Soavi L, Signorini L, Stellini R, et al. Linezolid and clindamycin improve the outcome of severe, necrotizing pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Infez Med. 2011;19:42-4.